Market analysis
The mastitis market is mainly growing because of the advancements made in the field of medical sciences. The growing prevalence of this type of contagious diseases amongst human beings, especially women and animals like cow are some of the major factor influencing the global mastitis market positively. Factors driving the market development incorporate the rising instances of breast-related disease and expanding rate of pregnancy. On account of bovines, the unhygienic animal dwelling place conditions are the key driving element behind the market development making the infectious mastitis spread. Besides, the rising awareness about the mastitis conditions, its effective management, and the accessibility of the treatment is broadly encouraging market development. The global mastitis market is growing at a CAGR of 15.07% by targeting the value of USD 7,898.05 million during the forecast period (2017-2023).



Market Segmentation
The global mastitis market has been divided on the basis of its treatment, type, end-user, and regional demand. Based on its type, the mastitis market is bifurcated into bovine mastitis and human mastitis. On the basis of its treatment, the mastitis market is classified into pain relievers, antibiotics, vaccines, surgery, and others. Based on its end-user, the mastitis market is segmented into clinics, hospitals, veterinary centers, and others.

Regional analysis
Geographically, the global mastitis market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players
Zoetis Inc. (U.S.), Boehringer Ingelheim GmbH (Germany), Merck Co & Inc. (U.S.), Astellas Pharma Inc. (Japan), Pfizer Inc. (U.S.), Novartis AG (Switzerland), BioNumerik Pharmaceuticals Inc. (U.S.), Bayer AG (Germany), Oncothyreon Inc. (U.S.), Oncogenex (U.S.), Apthera Inc. (U.K.), and others are some of the major players in the global mastitis market.